Rifapentine and Isoniazid for Latent Tuberculosis

被引：0
|
作者：
Mirsaeidi, Mehdi [1 ]
机构：
[1] Univ Illinois, Chicago, IL 60607 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2012年 / 366卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1447 / 1448
页数：2
相关论文
共 50 条
  • [31] Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study
    Radtke, Kendra K.
    Ernest, Jacqueline P.
    Zhang, Nan
    Ammerman, Nicole C.
    Nuermberger, Eric
    Belknap, Robert
    Boyd, Rosanna
    Sterling, Timothy R.
    Savic, Rada M.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (12)
  • [32] Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine
    McClintock, Adelaide H.
    Eastment, McKenna
    McKinney, Christy M.
    Pitney, Caroline L.
    Narita, Masahiro
    Park, David R.
    Dhanireddy, Shireesha
    Molnar, Alexandra
    BMC INFECTIOUS DISEASES, 2017, 17
  • [33] Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection
    Borisov, Andrey S.
    Morris, Sapna Bamrah
    Njie, Gibril J.
    Winston, Carla A.
    Burton, Deron
    Goldberg, Stefan
    Woodruff, Rachel Yelk
    Allen, Leeanna
    LoBue, Philip
    Vernon, Andrew
    MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2018, 67 (25): : 723 - 726
  • [34] Assessment for Antibodies to Rifapentine and Isoniazid in Persons Developing Flu-Like Reactions During Treatment of Latent Tuberculosis Infection
    Moro, Ruth N.
    Mehaffy, Carolina
    De, Prithwiraj
    Phillips, Elizabeth
    Borisov, Andrey S.
    Sterling, Timothy R.
    Dobos, Karen M.
    JOURNAL OF INFECTIOUS DISEASES, 2024, 230 (05): : 1271 - 1278
  • [35] Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan
    Sun, Hsin-Yun
    Huang, Yi-Wen
    Huang, Wei-Chang
    Chang, Lih-Yu
    Chan, Pei-Chun
    Chuang, Yu-Chung
    Ruan, Sheng-Yuan
    Wang, Jann-Yuan
    Wang, Jann-Tay
    TUBERCULOSIS, 2018, 111 : 121 - 126
  • [36] Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine
    Adelaide H. McClintock
    McKenna Eastment
    Christy M. McKinney
    Caroline L. Pitney
    Masahiro Narita
    David R. Park
    Shireesha Dhanireddy
    Alexandra Molnar
    BMC Infectious Diseases, 17
  • [37] In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis
    Chan, CY
    Au-Yeang, C
    Yew, WW
    Leung, CC
    Cheng, AFB
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (01) : 340 - 343
  • [38] Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis - Initial report
    Tam, CM
    Chan, SL
    Lam, CW
    Leung, CC
    Kam, KM
    Morris, JS
    Mitchison, DA
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 157 (06) : 1726 - 1733
  • [39] Role of isoniazid in once-weekly rifapentine treatment of pulmonary tuberculosis
    Mitchison, DA
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (10) : 1298 - 1299
  • [40] Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study
    Sterling, Timothy R.
    Moro, Ruth N.
    Borisov, Andrey S.
    Phillips, Elizabeth
    Shepherd, Gillian
    Adkinson, Newton Franklin
    Weis, Stephen
    Ho, Christine
    Villarino, Margarita Elsa
    CLINICAL INFECTIOUS DISEASES, 2015, 61 (04) : 527 - 535
12345